secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029009
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q4 revenue $68.7M (+10% YoY); net loss narrows to $0.5M; guides FY25 rev $224-230M
--------------------------------------------------------------------------------

- Q4 revenue $68.7M (+10% YoY); net loss ($0.5M) vs ($6.3M) in Q4 2023; adj. EBITDA $11.1M (322% improvement).
- Full-year 2024 revenue $209.4M (+12% YoY); net loss ($55.7M) vs ($49.5M); adj. EBITDA loss narrowed to ($11.0M) from ($24.4M).
- FY2025 revenue guidance $224M-$230M (7-10% growth); expects breakeven adj. EBITDA for full year.
- Entry into osteotomy market with Nanoplasty and Percuplasty 3D bunion systems; 280 new active surgeons added in 2024.
- Cash $75.7M plus $26M revolver access; patent portfolio 97 granted, 88 pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017025029009/0000950170-25-029009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017025029009/tmci-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer